Perrigo (PRGO) Other Non-Current Liabilities (2013 - 2026)
Perrigo's (PRGO) quarterly Other Non-Current Liabilities came in at $712.3 million in Q1 2026, up 31.54% year-on-year from $541.5 million in Q1 2025, and down 12.53% on a QoQ basis from $814.3 million in Q4 2025.
Perrigo (PRGO) Other Non-Current Liabilities (2013 - 2026) Analysis & Trends
Perrigo (PRGO) has 14 years of Other Non-Current Liabilities data on file, last reported at $712.3 million in Q1 2026.
- On a quarterly basis, Other Non-Current Liabilities rose 31.54% year-over-year to $712.3 million in Q1 2026; TTM through Mar 2026 was $712.3 million, a 31.54% increase from a year earlier, with the FY2025 full-year figure at $814.3 million, up 63.12% from the prior year.
- Other Non-Current Liabilities for Q1 2026 stood at $712.3 million, down from $814.3 million in the prior quarter.
- Over the last five years, Other Non-Current Liabilities for PRGO reached as high as $814.3 million in Q4 2025 and fell as low as $499.2 million in Q4 2024.
- Historically, Other Non-Current Liabilities has averaged $614.7 million across 5 years, with a median of $613.9 million in 2023.
- Across the five-year window, Other Non-Current Liabilities fell 18.72% in 2024 and jumped 63.12% in 2025, its largest moves.
- Year by year, Other Non-Current Liabilities stood at $623.0 million in 2022, then dropped by 10.14% to $559.8 million in 2023, then decreased by 10.83% to $499.2 million in 2024, then soared by 63.12% to $814.3 million in 2025, then fell by 12.53% to $712.3 million in 2026.
- Per Business Quant data, the three most recent Other Non-Current Liabilities figures were $712.3 million in Q1 2026, $814.3 million in Q4 2025, and $689.7 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Perrigo | 1.40 Bn | 1.05 Bn | 325.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 28, 2026 | 712.30 Mn |
| Dec 31, 2025 | 814.30 Mn |
| Sep 27, 2025 | 689.70 Mn |
| Jun 28, 2025 | 673.40 Mn |
| Mar 29, 2025 | 541.50 Mn |
| Dec 31, 2024 | 499.20 Mn |
| Sep 28, 2024 | 660.30 Mn |
| Jun 29, 2024 | 535.40 Mn |
| Mar 30, 2024 | 526.20 Mn |
| Dec 31, 2023 | 559.80 Mn |
| Sep 30, 2023 | 613.90 Mn |
| Jul 1, 2023 | 658.70 Mn |
| Apr 1, 2023 | 637.60 Mn |
| Dec 31, 2022 | 623.00 Mn |
| Oct 1, 2022 | 573.20 Mn |
| Jul 2, 2022 | 577.00 Mn |
| Apr 2, 2022 | 554.20 Mn |
| Dec 31, 2021 | 530.10 Mn |
| Oct 2, 2021 | 565.80 Mn |
| Jul 3, 2021 | 554.00 Mn |